shares of Sutro Biopharma Inc (STRO) on
Sutro Biopharma Inc. engages in the drug discovery, development, and manufacturing of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 169 full-time employees. The firm is focused on using its integrated cell-free protein synthesis platform, XpressCF, to create a variety of protein therapeutics for cancer and autoimmune disorders. The company focuses to design therapeutics using potent modalities, including cytokine-based immuno-oncology (I/O) therapeutics, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed primarily against clinically validated targets. Its product candidate includes STRO-001 and STRO-002. STRO-001 is an ADC directed against the cancer target CD74, for patients with multiple myeloma and non-Hodgkin lymphoma (NHL). STRO-002 is an ADC directed against folate receptor-alpha (FolRa), for patients with ovarian and endometrial cancers. STRO-001 and STRO-002 are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody using its XpressCF Platform.